サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：癌バイオマーカー市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
市場調査レポート
商品コード
1149261

癌バイオマーカー市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Cancer Biomarkers Market (Type: Protein, Genetics, and Others; and Type of Cancer: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Ovarian, Liver, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 225 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
癌バイオマーカー市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年09月14日
発行: Transparency Market Research
ページ情報: 英文 225 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の癌バイオマーカー市場について調査し、市場の概要とともに、2022年～2031年の予測、タイプ別、癌タイプ別、プロファイリング技術別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の癌バイオマーカー市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の癌バイオマーカー市場分析と予測、2017年～2031年

第5章 主な洞察

第6章 世界の癌バイオマーカー市場分析と予測、タイプ別

  • イントロダクションと定義
  • 主な調査結果/開発
  • タイプ別の市場価値予測、2017年～2031年
  • タイプ別の市場の魅力

第7章 世界の癌バイオマーカー市場分析と予測、癌タイプ別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 癌タイプ別の市場価値予測、2017年～2031年
  • 癌タイプ別の市場の魅力

第8章 世界癌バイオマーカー市場分析と予測、プロファイリング技術別

  • イントロダクションと定義
  • 主な調査結果/開発
  • プロファイリング技術別の市場価値予測、2017年～2031年
  • プロファイリング技術別の市場の魅力

第9章 世界の癌バイオマーカー市場分析と予測、用途別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 用途別の市場価値予測、2017年～2031年
  • 用途別の市場の魅力

第10章 世界の癌バイオマーカー市場分析と予測、地域別

  • 主な調査結果
  • 地域別の市場価値予測
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 国/地域別の市場の魅力

第11章 北米の癌バイオマーカー市場分析と予測

第12章 欧州の癌バイオマーカー市場分析と予測

第13章 アジア太平洋の癌バイオマーカー市場分析と予測

第14章 ラテンアメリカの癌バイオマーカー市場分析と予測

第15章 中東・アフリカの癌バイオマーカー市場分析と予測

第16章 競合情勢

  • 市場参入企業-競合マトリックス（層と企業規模別）
  • 企業別の市場シェア/ランキング分析（2021年）
  • 企業プロファイル
    • F. Hoffmann-LA Roche Ltd.
    • Thermo Fisher Scientific, Inc.
    • Abbott Laboratories
    • Bristol-Myers Squibb Company
    • PerkinElmer, Inc.
    • Qiagen NV
    • Siemens AG
    • Exact Sciences Corporation
    • Novartis AG
    • Bio-Rad Laboratories
    • Illumina
    • Agilent Technologies Inc.
    • Hologic, Inc.
    • bioMerieux SA
図表

List of Tables

  • Table 01: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 02: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 03: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 04: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 05: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 08: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 09: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 10: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 11: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
  • Table 12: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 13: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 14: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 15: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 18: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 19: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 20: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 21: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 23: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 24: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 25: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 26: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 28: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 29: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 30: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031

List of Figures

  • Figure 01: Global Cancer Biomarkers market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Cancer Biomarkers market Value Share, by Type, 2021
  • Figure 03: Global Cancer Biomarkers market Value Share, by Profiling Technology, 2021
  • Figure 04: Global Cancer Biomarkers market Value Share, by Cancer, 2021
  • Figure 05: Global Cancer Biomarkers market Value Share, by Application, 2021
  • Figure 06: Global Cancer Biomarkers market Value Share, by Region, 2021
  • Figure 07: Global Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 08: Global Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 09: Global Cancer Biomarkers Market Value (US$ Mn), by Protein, 2017-2031
  • Figure 10: Global Cancer Biomarkers Market Value (US$ Mn), by Genetic, 2017-2031
  • Figure 11: Global Cancer Biomarkers Market Value (US$ Mn), by Others, 2017-2031
  • Figure 12: Global Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 13: Global Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 14: Global Cancer Biomarkers Market Revenue (US$ Mn), by Lung, 2017-2031
  • Figure 15: Global Cancer Biomarkers Market Revenue (US$ Mn), by Breast, 2017-2031
  • Figure 16: Global Cancer Biomarkers Market Revenue (US$ Mn), by Leukemia, 2017-2031
  • Figure 17: Global Cancer Biomarkers Market Revenue (US$ Mn), by Melonoma, 2017-2031
  • Figure 18: Global Cancer Biomarkers Market Revenue (US$ Mn), by Colorectal, 2017-2031
  • Figure 19: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prostate, 2017-2031
  • Figure 20: Global Cancer Biomarkers Market Revenue (US$ Mn), by Ovarian, 2017-2031
  • Figure 21: Global Cancer Biomarkers Market Revenue (US$ Mn), by Liver, 2017-2031
  • Figure 22: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 23: Global Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 24: Global Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 25: Global Cancer Biomarkers Market Revenue (US$ Mn), by Omics, 2017-2031
  • Figure 26: Global Cancer Biomarkers Market Revenue (US$ Mn), by Imaging, 2017-2031
  • Figure 27: Global Cancer Biomarkers Market Revenue (US$ Mn), by Immunoassay, 2017-2031
  • Figure 28: Global Cancer Biomarkers Market Revenue (US$ Mn), by Bioinformatics, 2017-2031
  • Figure 29: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 30: Global Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 31: Global Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 32: Global Cancer Biomarkers Market Revenue (US$ Mn), by Diagnostics, 2017-2031
  • Figure 33: Global Cancer Biomarkers Market Revenue (US$ Mn), by R&D, 2017-2031
  • Figure 34: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prognostics, 2017-2031
  • Figure 35: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 36: Global Cancer Biomarkers Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 37: Global Cancer Biomarkers Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 38: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 39: North America Cancer Biomarkers Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 40: North America Cancer Biomarkers Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 41: North America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 42: North America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 43: North America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 44: North America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 45: North America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 46: North America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 47: North America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 48: North America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 49: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Europe Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 51: Europe Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 52: Europe Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

Figure53 11: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031

  • Figure 54: Europe Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 55: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 56: Europe Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 57: Europe Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 58: Europe Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 59: Europe Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 60: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 62: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 63: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 64: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 65: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 66: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 67: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 68: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 69: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 70: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 71: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 72: Latin America Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
  • Figure 73: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
  • Figure 74: Latin America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 75: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 76: Latin America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 77: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 78: Latin America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 79: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 80: Latin America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 81: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 82: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 83: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
  • Figure 84: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
  • Figure 85: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 86: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 87: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 88: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 89: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 90: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 91: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 92: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
目次
Product Code: TMRGL479

The report provides revenue of the global cancer biomarkers market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer biomarkers market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cancer biomarkers market.

The report delves into the competitive landscape of the global cancer biomarkers market. Key players operating in the global cancer biomarkers market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global cancer biomarkers market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Biomarkers Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cancer Biomarkers Market Analysis and Forecasts, 2017 - 2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Cancer Biomarkers Market Analysis and Forecasts, By Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Type, 2017 - 2031
    • 6.3.1. Protein
    • 6.3.2. Genetic
    • 6.3.3. Others
  • 6.4. Market Attractiveness By Type

7. Global Cancer Biomarkers Market Analysis and Forecasts, By Type of Cancer

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 7.3.1. Lung
    • 7.3.2. Breast
    • 7.3.3. Leukemia
    • 7.3.4. Melanoma
    • 7.3.5. Colorectal
    • 7.3.6. Prostate
    • 7.3.7. Ovarian
    • 7.3.8. Liver
    • 7.3.9. Others
  • 7.4. Market Attractiveness By Type of Cancer

8. Global Cancer Biomarkers Market Analysis and Forecasts, By Profiling Technology

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 8.3.1. Omics
    • 8.3.2. Imaging
    • 8.3.3. Immunoassay
    • 8.3.4. Bioinformatics
    • 8.3.5. Others
  • 8.4. Market Attractiveness By Profiling Technology

9. Global Cancer Biomarkers Market Analysis and Forecasts, By Application

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Application, 2017 - 2031
    • 9.3.1. Diagnostics
    • 9.3.2. R&D
    • 9.3.3. Prognostics
    • 9.3.4. Others
  • 9.4. Market Attractiveness By Application

10. Global Cancer Biomarkers Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America Cancer Biomarkers Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Type, 2017 - 2031
    • 11.2.1. Protein
    • 11.2.2. Genetic
    • 11.2.3. Others
  • 11.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 11.3.1. Lung
    • 11.3.2. Breast
    • 11.3.3. Leukemia
    • 11.3.4. Melanoma
    • 11.3.5. Colorectal
    • 11.3.6. Prostate
    • 11.3.7. Ovarian
    • 11.3.8. Liver
    • 11.3.9. Others
  • 11.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 11.4.1. Omics
    • 11.4.2. Imaging
    • 11.4.3. Immunoassay
    • 11.4.4. Bioinformatics
    • 11.4.5. Others
  • 11.5. Market Value Forecast By Application, 2017 - 2031
    • 11.5.1. Diagnostics
    • 11.5.2. R&D
    • 11.5.3. Prognostics
    • 11.5.4. Others
  • 11.6. Market Value Forecast By Country, 2017 - 2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Type of Cancer
    • 11.7.3. By Profiling Technology
    • 11.7.4. By Application
    • 11.7.5. By Country

12. Europe Cancer Biomarkers Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Type, 2017 - 2031
    • 12.2.1. Protein
    • 12.2.2. Genetic
    • 12.2.3. Others
  • 12.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 12.3.1. Lung
    • 12.3.2. Breast
    • 12.3.3. Leukemia
    • 12.3.4. Melanoma
    • 12.3.5. Colorectal
    • 12.3.6. Prostate
    • 12.3.7. Ovarian
    • 12.3.8. Liver
    • 12.3.9. Others
  • 12.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 12.4.1. Omics
    • 12.4.2. Imaging
    • 12.4.3. Immunoassay
    • 12.4.4. Bioinformatics
    • 12.4.5. Others
  • 12.5. Market Value Forecast By Application, 2017 - 2031
    • 12.5.1. Diagnostics
    • 12.5.2. R&D
    • 12.5.3. Prognostics
    • 12.5.4. Others
  • 12.6. Market Value Forecast By Country/Sub-region, 2017 - 2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Type of Cancer
    • 12.7.3. By Profiling Technology
    • 12.7.4. By Application
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Cancer Biomarkers Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Type, 2017 - 2031
    • 13.2.1. Protein
    • 13.2.2. Genetic
    • 13.2.3. Others
  • 13.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 13.3.1. Lung
    • 13.3.2. Breast
    • 13.3.3. Leukemia
    • 13.3.4. Melanoma
    • 13.3.5. Colorectal
    • 13.3.6. Prostate
    • 13.3.7. Ovarian
    • 13.3.8. Liver
    • 13.3.9. Others
  • 13.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 13.4.1. Omics
    • 13.4.2. Imaging
    • 13.4.3. Immunoassay
    • 13.4.4. Bioinformatics
    • 13.4.5. Others
  • 13.5. Market Value Forecast By Application, 2017 - 2031
    • 13.5.1. Diagnostics
    • 13.5.2. R&D
    • 13.5.3. Prognostics
    • 13.5.4. Others
  • 13.6. Market Value Forecast By Country/Sub-region, 2017 - 2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Type of Cancer
    • 13.7.3. By Profiling Technology
    • 13.7.4. By Application
    • 13.7.5. By Country/Sub-region

14. Latin America Cancer Biomarkers Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Type, 2017 - 2031
    • 14.2.1. Protein
    • 14.2.2. Genetic
    • 14.2.3. Others
  • 14.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 14.3.1. Lung
    • 14.3.2. Breast
    • 14.3.3. Leukemia
    • 14.3.4. Melanoma
    • 14.3.5. Colorectal
    • 14.3.6. Prostate
    • 14.3.7. Ovarian
    • 14.3.8. Liver
    • 14.3.9. Others
  • 14.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 14.4.1. Omics
    • 14.4.2. Imaging
    • 14.4.3. Immunoassay
    • 14.4.4. Bioinformatics
    • 14.4.5. Others
  • 14.5. Market Value Forecast By Application, 2017 - 2031
    • 14.5.1. Diagnostics
    • 14.5.2. R&D
    • 14.5.3. Prognostics
    • 14.5.4. Others
  • 14.6. Market Value Forecast By Country/Sub-region, 2017 - 2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Type of Cancer
    • 14.7.3. By Profiling Technology
    • 14.7.4. By Application
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Cancer Biomarkers Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Type, 2017 - 2031
    • 15.2.1. Protein
    • 15.2.2. Genetic
    • 15.2.3. Others
  • 15.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 15.3.1. Lung
    • 15.3.2. Breast
    • 15.3.3. Leukemia
    • 15.3.4. Melanoma
    • 15.3.5. Colorectal
    • 15.3.6. Prostate
    • 15.3.7. Ovarian
    • 15.3.8. Liver
    • 15.3.9. Others
  • 15.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 15.4.1. Omics
    • 15.4.2. Imaging
    • 15.4.3. Immunoassay
    • 15.4.4. Bioinformatics
    • 15.4.5. Others
  • 15.5. Market Value Forecast By Application, 2017 - 2031
    • 15.5.1. Diagnostics
    • 15.5.2. R&D
    • 15.5.3. Prognostics
    • 15.5.4. Others
  • 15.6. Market Value Forecast By Country/Sub-region, 2017 - 2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Type
    • 15.7.2. By Type of Cancer
    • 15.7.3. By Profiling Technology
    • 15.7.4. By Application
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share/Ranking Analysis By Company (2021)
  • 16.3. Company Profiles
    • 16.3.1. F. Hoffmann-LA Roche Ltd.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. SWOT Analysis
      • 16.3.1.4. Strategic Overview
    • 16.3.2. Thermo Fisher Scientific, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. SWOT Analysis
      • 16.3.2.4. Strategic Overview
    • 16.3.3. Abbott Laboratories
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. SWOT Analysis
      • 16.3.3.4. Strategic Overview
    • 16.3.4. Bristol-Myers Squibb Company
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. SWOT Analysis
      • 16.3.4.4. Strategic Overview
    • 16.3.5. PerkinElmer, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. SWOT Analysis
      • 16.3.5.4. Strategic Overview
    • 16.3.6. Qiagen N.V.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. SWOT Analysis
      • 16.3.6.4. Strategic Overview
    • 16.3.7. Siemens AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. SWOT Analysis
      • 16.3.7.4. Strategic Overview
    • 16.3.8. Exact Sciences Corporation
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. SWOT Analysis
      • 16.3.8.4. Strategic Overview
    • 16.3.9. Novartis AG
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. SWOT Analysis
      • 16.3.9.4. Strategic Overview
    • 16.3.10. Bio-Rad Laboratories
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. SWOT Analysis
      • 16.3.10.4. Strategic Overview
    • 16.3.11. Illumina
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. SWOT Analysis
      • 16.3.11.4. Strategic Overview
    • 16.3.12. Agilent Technologies Inc.
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. SWOT Analysis
      • 16.3.12.4. Strategic Overview
    • 16.3.13. Hologic, Inc.
      • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.13.2. Product Portfolio
      • 16.3.13.3. SWOT Analysis
      • 16.3.13.4. Strategic Overview
    • 16.3.14. bioMerieux SA
      • 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.14.2. Product Portfolio
      • 16.3.14.3. SWOT Analysis
      • 16.3.14.4. Strategic Overview